Top

Published in:

01-10-2018 | Laboratory Investigation

RUNX3 inhibits glioma survival and invasion via suppression of the β-catenin/TCF-4 signaling pathway

Authors: Jikui Sun, Banban Li, Zhifan Jia, Anling Zhang, Guangxiu Wang, Zhijuan Chen, Zhende Shang, Chaocai Zhang, Jian Cui, Weidong Yang

Published in: Journal of Neuro-Oncology | Issue 1/2018

Abstract

Introduction

Runt-related transcription factor 3 (RUNX3) exerts a tumor suppressor gene associated with gastric and other cancers, including glioma. However, how its anti-tumor mechanism in functions glioma is unclear.

Methods

We assayed expression of RUNX3 with a tissue microarray (TMA), frozen cancer tissues and malignant glioma cell lines using immunohistochemistry, qRT-PCR and Western bolt analysis. Cell proliferation, invasion, cell cycle distribution and apoptosis were also examined to confirm the effect of RUNX3 medicated malignant phenotype. TOP/FOP experiment was used to detect the β-catenin/Tcf-4 transcription activity by RUNX3.

Results

Enforced RUNX3 expression inhibited proliferation and invasion, induced cell cycle arrest and promoted apoptosis in vitro and in vivo, Bim siRNA partically reversed the effect of RUNX3-induced apoptosis in LN229 and U87 cells, suggesting a dependent role of Bim-caspase pathway. Moreover, Mechanism investigations revealed that restoration of RUNX3 suppressed β-catenin/Tcf-4 transcription activity.

Conclusions

RUNX3 plays a pivotal role in glioma initiation and progression as a tumor suppressor via attenuation of Wnt signaling, highlighting it as a potential therapeutic target for glioma.

Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD, Yan H, Adamson C (2009) Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol 3:39–52PubMedPubMedCentral

Zhang K, Zhang J, Han L, Pu P, Kang C (2012) Wnt/beta-catenin signaling in glioma. J Neuroimmune Pharmacol 7:740–749. https://doi.org/10.1007/s11481-012-9359-y CrossRefPubMed

Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, Louis DN (2007) Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 26:583–593. https://doi.org/10.1038/sj.onc.1209805 CrossRefPubMed

Ito Y, Miyazono K (2003) RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev 13:43–47CrossRefPubMed

Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:113–124CrossRefPubMed

Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, Jia ZF, Yang WD, Wang GX, Jiang T, You YP, Pu PY, Cheng JQ, Kang CS (2010) MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9:229. https://doi.org/10.1186/1476-4598-9-229 CrossRefPubMedPubMedCentral

Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, Wang B, Wang G, Jia Z, Pu P, Zhang W, Kang C (2010) Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Investig: J Tech Methods Pathol 90:144–155. https://doi.org/10.1038/labinvest.2009.126 CrossRef

Shi Z, Qian X, Li L, Zhang J, Zhu S, Zhu J, Chen L, Zhang K, Han L, Yu S, Pu P, Jiang T, Kang C (2012) Nuclear translocation of beta-catenin is essential for glioma cell survival. J Neuroimmune Pharmacol 7:892–903. https://doi.org/10.1007/s11481-012-9354-3 CrossRefPubMed

Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K (2011) A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 71:154–163. https://doi.org/10.1158/0008-5472.CAN-10-1601 CrossRefPubMed

10.

Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, Lim XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y, Soong R, Singapore Gastric Cancer C (2010) MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer 46:1456–1463. https://doi.org/10.1016/j.ejca.2010.01.036 CrossRefPubMed

11.

Zuo J, Xia J, Ju F, Yan J, Zhu A, Jin S, Shan T, Zhou H (2013) MicroRNA-148a can regulate runt-related transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer. Mol Cells 35:313–319. https://doi.org/10.1007/s10059-013-2314-9 CrossRefPubMedPubMedCentral

12.

Lin FC, Liu YP, Lai CH, Shan YS, Cheng HC, Hsu PI, Lee CH, Lee YC, Wang HY, Wang CH, Cheng JQ, Hsiao M, Lu PJ (2012) RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. Oncogene 31:4302–4316. https://doi.org/10.1038/onc.2011.596 CrossRefPubMed

13.

Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, Fukamachi H, Ito Y (2008) RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14:226–237. https://doi.org/10.1016/j.ccr.2008.08.004 CrossRefPubMed

14.

Markowitz SD, Roberts AB (1996) Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 7:93–102CrossRefPubMed

15.

Ramjaun AR, Tomlinson S, Eddaoudi A, Downward J (2007) Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis. Oncogene 26:970–981. https://doi.org/10.1038/sj.onc.1209852 CrossRefPubMed

16.

Wei D, Gong W, Oh SC, Li Q, Kim WD, Wang L, Le X, Yao J, Wu TT, Huang S, Xie K (2005) Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 65:4809–4816. https://doi.org/10.1158/0008-5472.CAN-04-3741 CrossRefPubMed

17.

Torquati A, O’Rear L, Longobardi L, Spagnoli A, Richards WO, Daniel Beauchamp R (2004) RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery 136:310–316. https://doi.org/10.1016/j.surg.2004.05.005 CrossRefPubMed

18.

Nakanishi Y, Shiraha H, Nishina S, Tanaka S, Matsubara M, Horiguchi S, Iwamuro M, Takaoka N, Uemura M, Kuwaki K, Hagihara H, Toshimori J, Ohnishi H, Takaki A, Nakamura S, Kobayashi Y, Nouso K, Yagi T, Yamamoto K (2011) Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. BMC Cancer 11:3. https://doi.org/10.1186/1471-2407-11-3 CrossRefPubMedPubMedCentral

19.

Yamamura Y, Lee WL, Inoue K, Ida H, Ito Y (2006) RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem 281:5267–5276. https://doi.org/10.1074/jbc.M512151200 CrossRefPubMed

20.

Sampieri CL, Leon-Cordoba K, Remes-Troche JM (2013) Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers. J Cancer Res Ther 9:356–363. https://doi.org/10.4103/0973-1482.119302 CrossRefPubMed

21.

Mei PJ, Bai J, Liu H, Li C, Wu YP, Yu ZQ, Zheng JN (2011) RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol 137:1823–1830. https://doi.org/10.1007/s00432-011-1063-4 CrossRefPubMed

22.

He L, Zhao X, Wang H, Zhang P, Guo C, Huang C, Liu X, Yao F, Chen Y, Lou W, Sun S, Fan D (2012) RUNX3 mediates suppression of tumor growth and metastasis of human CCRCC by regulating cyclin related proteins and TIMP-1. PLoS ONE 7:e32961. https://doi.org/10.1371/journal.pone.0032961 CrossRefPubMedPubMedCentral

23.

Chen Y, Wei X, Guo C, Jin H, Han Z, Han Y, Qiao T, Wu K, Fan D (2011) Runx3 suppresses gastric cancer metastasis through inactivation of MMP9 by upregulation of TIMP-1. Int J Cancer 129:1586–1598. https://doi.org/10.1002/ijc.25831 CrossRefPubMed

24.

Rundhaug JE (2005) Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9:267–285CrossRefPubMed

25.

Peng Z, Wei D, Wang L, Tang H, Zhang J, Le X, Jia Z, Li Q, Xie K (2006) RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 12:6386–6394. https://doi.org/10.1158/1078-0432.CCR-05-2359 CrossRef

26.

Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, Ushijima T, Kim WJ, Ito Y, Bae SC (2005) RUNX3 suppresses gastric epithelial cell growth by inducing p21 (WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 25:8097–8107. https://doi.org/10.1128/MCB.25.18.8097-8107.2005 CrossRefPubMedPubMedCentral

27.

Min B, Kim MK, Zhang JW, Kim J, Chung KC, Oh BC, Stein GS, Lee YH, van Wijnen AJ, Bae SC (2012) Identification of RUNX3 as a component of the MST/Hpo signaling pathway. J Cell Physiol 227:839–849. https://doi.org/10.1002/jcp.22887 CrossRefPubMedPubMedCentral

Title: RUNX3 inhibits glioma survival and invasion via suppression of the β-catenin/TCF-4 signaling pathway
Authors: Jikui Sun
Banban Li
Zhifan Jia
Anling Zhang
Guangxiu Wang
Zhijuan Chen
Zhende Shang
Chaocai Zhang
Jian Cui
Weidong Yang
Publication date: 01-10-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2927-0

At a glance: The STEP trials

Springer Medicine

RUNX3 inhibits glioma survival and invasion via suppression of the β-catenin/TCF-4 signaling pathway

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Spinal meningioma and factors predictive of post-operative deterioration

Postoperative seizures in meningioma patients: improving patient selection for antiepileptic drug therapy

Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making

Clinical features, treatments and long-term follow-up outcomes of spinal chondroblastoma: report of 13 clinical cases in a single center

A missing piece? Neuropsychiatric functioning in untreated patients with tumors within the cerebellopontine angle

Optimal strategy of gamma knife radiosurgery for craniopharyngiomas